Race influences the safety and efficacy of spironolactone in severe heart failure

Circulation: Heart Failure

Volumn 6, Issue 5, 2013, Pages 970-976

  Vardeny, Orly ^a   Cavallari, Larisa H ^b   Claggett, Brian ^c   Desai, Akshay S ^c   Anand, Inder ^d   Rossignol, Patrick ^e   Zannad, Faiez ^e   Pitt, Bertram ^f   Solomon, Scott D ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITÉ DE LORRAINE   (France)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Heart failure; Pharmacology; Potassium

Indexed keywords

ACETYLSALICYLIC ACID; DIGOXIN; POTASSIUM; SPIRONOLACTONE;

ADULT; AFRICAN AMERICAN; ARTICLE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RACE;

HEART FAILURE; PHARMACOLOGY; POTASSIUM;

ADULT; AFRICAN AMERICANS; AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART FAILURE; HUMANS; HYPERKALEMIA; HYPOKALEMIA; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PATIENT SELECTION; POTASSIUM; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84887475280     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000530     Document Type: Article

References (33)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
3. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
4. Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, Casey DE Jr, McMurray JJ, Drazner MH, Mitchell JE, Fonarow GC, Peterson PN, Geraci SA, Horwich T, Januzzi JL Johnson MR, Kasper EK, Levy WC, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; ACCF/AHA Task Force Members. J Am Coll Cardiol. 2013 Jun 5. doi: pii: S0735-1097(13)02114-1. 10.1016/j.jacc.2013.05.019 [Epub ahead of print].
5. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1-e194.
6. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
7. Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ. 2010;340:c1768.
8. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA. 2009;302:1658-1665.
9. Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail. 2008;1:98-106.
10. Cavallari LH, Fashingbauer LA, Beitelshees AL, Groo VL, Southworth MR, Viana MA, Williams RE, Dunlap SH. Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. Pharmacotherapy. 2004;24:750-756.
11. Cavallari LH, Groo VL, Momary KM, Fontana D, Viana MA, Vaitkus P. Racial differences in potassium response to spironolactone in heart failure. Congest Heart Fail. 2006;12:200-205.
12. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178-187.
13. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
14. Palmer BF. Managing hyperkalemia caused by inhibitors of the reninangiotensin- aldosterone system. N Engl J Med. 2004;351:585-592.
15. Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep. 2009;6:272-280.
16. Ghali JK, Tam SW, Sabolinski ML, Taylor AL, Lindenfeld J, Cohn JN, Worcel M. Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial. J Card Fail. 2008;14:718-723.
17. Bagchi AD, Esposito D, Kim M, Verdier J, Bencio D. Utilization of, and adherence to, drug therapy among medicaid beneficiaries with congestive heart failure. Clin Ther. 2007;29:1771-1783.
18. Wu JR, Chung M, Lennie TA, Hall LA, Moser DK. Testing the psychometric properties of the Medication Adherence Scale in patients with heart failure. Heart Lung. 2008;37:334-343.
19. Wu JR, Lennie TA, De Jong MJ, Frazier SK, Heo S, Chung ML, Moser DK. Medication adherence is a mediator of the relationship between ethnicity and event-free survival in patients with heart failure. J Card Fail. 2010;16:142-149.
20. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin- converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
21. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB; ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595-1608.
22. Lanfear DE, Hrobowski TN, Peterson EL, Wells KE, Swadia TV, Spertus JA, Williams LK. Association of β-blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail. 2012;5:202-208.
23. Goldstein S, Deedwania P, Gottlieb S, Wikstrand J; MERIT-HF Study Group. Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). Am J Cardiol. 2003;92:478-480.
24. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M; U.S. Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358-1365.
25. Sica DA, Hess M. Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure. Congest Heart Fail. 2004;10:259-264.
26. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Piña IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33:2782-2795.
27. Arai K, Nakagomi Y, Iketani M, Shimura Y, Amemiya S, Ohyama K, Shibasaki T. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism. Hum Genet. 2003;112:91-97.
28. Cavallari LH, Groo VL, Viana MA, Dai Y, Patel SR, Stamos TD. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. Pharmacotherapy. 2010;30:1-9.
29. Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58:1958-1966.
30. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5:531-548.
31. Alper AB, Campbell RC, Anker SD, Bakris G, Wahle C, Love TE, Hamm LL, Mujib M, Ahmed A. A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol. 2009;137:1-8.
32. Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM, Bakris GL, Ahmed A. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010;3:253-260.
33. Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, Pitt B. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J. 2007;28:1334-1343.